BioMarin Pharmaceutical (NASDAQ:BMRN) Cut to Hold at Wall Street Zen

Wall Street Zen cut shares of BioMarin Pharmaceutical (NASDAQ:BMRN) from a buy rating to a hold rating in a research report sent to investors on Saturday morning,Wall Street Zen reports.

BMRN has been the subject of a number of other reports. Barclays lifted their price target on shares of BioMarin Pharmaceutical from $111.00 to $114.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 14th. Raymond James Financial raised shares of BioMarin Pharmaceutical from an “outperform” rating to a “strong-buy” rating and set a $109.00 price objective for the company in a research note on Monday, October 12th. Weiss Ratings downgraded shares of BioMarin Pharmaceutical from a “sell (d+)” rating to a “sell (d)” rating in a research note on Friday, September 18th. BMO Capital Markets restated an “outperform” rating on shares of BioMarin Pharmaceutical in a research report on Wednesday, September 16th. Finally, Piper Sandler upped their target price on BioMarin Pharmaceutical from $88.00 to $90.00 and gave the company an “overweight” rating in a research note on Tuesday, September 1st. Three investment analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating, six have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, BioMarin Pharmaceutical presently has a consensus rating of “Moderate Buy” and a consensus target price of $88.39.

BioMarin Pharmaceutical Stock Performance

NASDAQ:BMRN opened at $57.44 on Friday. The stock’s fifty day moving average is $60.43 and its 200 day moving average is $58.46. BioMarin Pharmaceutical has a fifty-two week low of $49.26 and a fifty-two week high of $70.98. The firm has a market capitalization of $11.12 billion, a PE ratio of 33.33, a PEG ratio of 0.61 and a beta of 0.22. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.32 and a current ratio of 2.39.

BioMarin Pharmaceutical (NASDAQ:BMRN) last issued its quarterly earnings results on Monday, November 2nd. The biotechnology company reported $0.23 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.31. BioMarin Pharmaceutical had a return on equity of 5.32% and a net margin of 2.14%. The company had revenue of $1.02 billion during the quarter, compared to the consensus estimate of $1.02 billion. During the same period last year, the company earned $0.12 earnings per share. BioMarin Pharmaceutical’s revenue was up 32.0% on a year-over-year basis. On average, sell-side analysts anticipate that BioMarin Pharmaceutical will post 2.59 earnings per share for the current year.

Institutional Investors Weigh In On BioMarin Pharmaceutical

Several hedge funds have recently made changes to their positions in the company. Parkside Financial Bank & Trust raised its holdings in shares of BioMarin Pharmaceutical by 70.3% in the second quarter. Parkside Financial Bank & Trust now owns 453 shares of the biotechnology company’s stock valued at $26,000 after acquiring an additional 187 shares in the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. bought a new position in BioMarin Pharmaceutical during the 2nd quarter worth about $39,000. Keating Financial Advisory Services Inc. bought a new position in BioMarin Pharmaceutical during the 2nd quarter worth about $56,000. Root Financial Partners LLC purchased a new position in BioMarin Pharmaceutical during the 3rd quarter valued at about $88,000. Finally, Parallel Advisors LLC increased its position in BioMarin Pharmaceutical by 33.9% during the 1st quarter. Parallel Advisors LLC now owns 1,768 shares of the biotechnology company’s stock valued at $100,000 after purchasing an additional 448 shares during the period. 98.71% of the stock is currently owned by hedge funds and other institutional investors.

Trending Headlines about BioMarin Pharmaceutical

Here are the key news stories impacting BioMarin Pharmaceutical this week:

• Positive Sentiment: Third-quarter adjusted earnings were $0.23 per share, well above the consensus estimate for a loss of approximately $0.08–$0.09 and up from $0.12 a year earlier. Revenue rose 32% year over year to $1.025 billion, broadly matching analyst expectations. BioMarin Pharmaceutical Q3 Earnings Surpass Estimates
• Positive Sentiment: Growth was broad-based, led by a 44% increase in revenue from metabolic-condition products and a 12% gain in skeletal-condition products. These results indicate continued commercial momentum across BioMarin’s portfolio. BioMarin Reports Third Quarter 2026 Financial and Operating Results
• Positive Sentiment: BioMarin added a new investigational Fabry disease asset to its clinical pipeline and received a May 30, 2027 PDUFA action date for VOXZOGO in hypochondroplasia, providing potential future catalysts. BioMarin Reports Third Quarter 2026 Financial and Operating Results
• Neutral Sentiment: Quarterly revenue was in line with forecasts, suggesting the results did not materially exceed expectations despite the earnings beat. BioMarin Q3 Revenue Earnings Flash
• Negative Sentiment: Management lowered 2026 guidance, citing uncertainty around order timing and the impact of two acquired in-process research and development charges. Reports also characterized the revised full-year sales outlook as below expectations, raising concerns about near-term growth and visibility. BioMarin Q3 Results and Lowered Guidance

BioMarin Pharmaceutical Company Profile

BioMarin Pharmaceutical Inc is a biotechnology company focused on developing and commercializing therapies for serious and life-threatening rare diseases. The company’s research and development efforts center on genetic and metabolic disorders, where patient populations are often small and treatment options are limited.

BioMarin’s marketed products include Voxzogo (vosoritide) for children with achondroplasia and open growth plates, Palynziq (pegvaliase) and Kuvan (sapropterin dihydrochloride) for phenylketonuria, Brineura (cerliponase alfa) for late-infantile neuronal ceroid lipofuscinosis type 2, Vimizim (elosulfase alfa) for Morquio A syndrome, and Naglazyme (galsulfase) for mucopolysaccharidosis VI.